Shanshan He1, Bowen Ding1, Gang Li2, Yubei Huang3, Chunyong Han1, Jingyan Sun1, Qingfeng Huang1, Jing Liu1, Zhuming Yin1, Shu Wang1, Jian Yin1. 1. Department of Breast Reconstruction, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Sino-Russian Joint Research Center for Oncoplastic Breast Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China. 2. School of Pharmacy, University College London, London WC1N 1AX, UK. 3. Department of Cancer Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Abstract
OBJECTIVE: The number of immediate breast reconstruction (IBR) procedures has been increasing in China. This study aimed to investigate the oncological safety of IBR, and to compare the survival and surgical outcomes between implant-based and autologous reconstruction. METHODS: Data from patients diagnosed with invasive breast cancer who underwent immediate total breast reconstruction between 2001 and 2016 were retrospectively reviewed. Long-term breast cancer-specific survival (BCSS), disease-free survival (DFS), and locoregional recurrence-free survival (LRFS) were evaluated. Patient satisfaction with the breast was compared between the implant-based and autologous groups. BCSS, DFS, and LRFS were compared between groups after propensity score matching (PSM). RESULTS: A total of 784 IBR procedures were identified, of which 584 were performed on patients with invasive breast cancer (implant-based, n = 288; autologous, n = 296). With a median follow-up of 71.3 months, the 10-year estimates of BCSS, DFS, and LRFS were 88.9% [95% confidence interval (CI) (85.1%-93.0%)], 79.6% [95% CI (74.7%-84.8%)], and 94.0% [95% CI (90.3%-97.8%)], respectively. A total of 124 patients completed the Breast-Q questionnaire, and no statistically significant differences were noted between groups (P = 0.823). After PSM with 27 variables, no statistically significant differences in BCSS, DFS, and LRFS were found between the implant-based (n = 177) and autologous (n = 177) groups. Further stratification according to staging, histological grade, lymph node status, and lymph-venous invasion status revealed no significant survival differences between groups. CONCLUSIONS: Both immediate implant-based and autologous reconstruction were reasonable choices with similar long-term oncological outcomes and patient-reported satisfaction among patients with invasive breast cancer in China.
OBJECTIVE: The number of immediate breast reconstruction (IBR) procedures has been increasing in China. This study aimed to investigate the oncological safety of IBR, and to compare the survival and surgical outcomes between implant-based and autologous reconstruction. METHODS: Data from patients diagnosed with invasive breast cancer who underwent immediate total breast reconstruction between 2001 and 2016 were retrospectively reviewed. Long-term breast cancer-specific survival (BCSS), disease-free survival (DFS), and locoregional recurrence-free survival (LRFS) were evaluated. Patient satisfaction with the breast was compared between the implant-based and autologous groups. BCSS, DFS, and LRFS were compared between groups after propensity score matching (PSM). RESULTS: A total of 784 IBR procedures were identified, of which 584 were performed on patients with invasive breast cancer (implant-based, n = 288; autologous, n = 296). With a median follow-up of 71.3 months, the 10-year estimates of BCSS, DFS, and LRFS were 88.9% [95% confidence interval (CI) (85.1%-93.0%)], 79.6% [95% CI (74.7%-84.8%)], and 94.0% [95% CI (90.3%-97.8%)], respectively. A total of 124 patients completed the Breast-Q questionnaire, and no statistically significant differences were noted between groups (P = 0.823). After PSM with 27 variables, no statistically significant differences in BCSS, DFS, and LRFS were found between the implant-based (n = 177) and autologous (n = 177) groups. Further stratification according to staging, histological grade, lymph node status, and lymph-venous invasion status revealed no significant survival differences between groups. CONCLUSIONS: Both immediate implant-based and autologous reconstruction were reasonable choices with similar long-term oncological outcomes and patient-reported satisfaction among patients with invasive breast cancer in China.
Authors: Christopher J Coroneos; Karina Roth-Albin; Ajit S Rai; Amrit S Rai; Sophocles H Voineskos; Melissa C Brouwers; Ronen Avram; Barbara Heller Journal: Breast Date: 2016-12-28 Impact factor: 4.380
Authors: F C J Reinders; D A Young-Afat; M C T Batenburg; S E Bruekers; E A van Amerongen; J F M Macaré van Maurik; A Braakenburg; E Zonnevylle; M Hoefkens; T Teunis; H M Verkooijen; H J G D van den Bongard; W Maarse Journal: Breast Cancer Date: 2019-12-19 Impact factor: 4.239
Authors: Andrea L Pusic; Evan Matros; Neil Fine; Edward Buchel; Gayle M Gordillo; Jennifer B Hamill; Hyungjin M Kim; Ji Qi; Claudia Albornoz; Anne F Klassen; Edwin G Wilkins Journal: J Clin Oncol Date: 2017-03-27 Impact factor: 44.544
Authors: Kyeong-Tae Lee; Sungjin Kim; Byung-Joon Jeon; Jai Kyong Pyon; Goo-Hyun Mun; Jai Min Ryu; Se Kyung Lee; Jonghan Yu; Seok Won Kim; Jeong Eon Lee; Seok Jin Nam; Sa Ik Bang Journal: JAMA Surg Date: 2020-12-01 Impact factor: 14.766
Authors: Shelley Potter; Elizabeth J Conroy; Ramsey I Cutress; Paula R Williamson; Lisa Whisker; Steven Thrush; Joanna Skillman; Nicola L P Barnes; Senthurun Mylvaganam; Elisabeth Teasdale; Abhilash Jain; Matthew D Gardiner; Jane M Blazeby; Chris Holcombe Journal: Lancet Oncol Date: 2019-01-09 Impact factor: 41.316